<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00521248</url>
  </required_header>
  <id_info>
    <org_study_id>R21DA018207-01</org_study_id>
    <secondary_id>R21DA018207-01</secondary_id>
    <secondary_id>DPMC</secondary_id>
    <nct_id>NCT00521248</nct_id>
  </id_info>
  <brief_title>Buprenorphine for the Treatment of Neonatal Abstinence Syndrome</brief_title>
  <official_title>Buprenorphine for the Treatment of Neonatal Abstinence Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute on Drug Abuse (NIDA)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neonatal abstinence syndrome is a disease that affects children who were exposed to opioid
      drugs prior to birth. Commonly used treatments at present include morphine or tincture of
      opium. Buprenorphine is a drug used in adults to treat narcotic dependence, but has not been
      used for Neonatal Abstinence Syndrome. This trial is designed to see if the use of sublingual
      (under the tongue) buprenorphine is able to be used safely and easily in newborns with the
      neonatal abstinence syndrome. Secondary goals will be to see if treatment with buprenorphine
      is associated shorter stays in the hospital and fewer days of treatment than the use of
      standard therapy. Another secondary goal will be to understand buprenorphine concentration in
      the blood of babies treated with the drug (this is called &quot;pharmacokinetics&quot;).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sublingual Buprenorphine safety and tolerability in the neonate</measure>
    <time_frame>Index hospitalization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Buprenorphine Pharmacokinetics</measure>
    <time_frame>Index hospitalization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Length of treatment</measure>
    <time_frame>Index hospitalization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Length of hospitalization</measure>
    <time_frame>Index hospitalization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Neonatal Abstinence Syndrome</condition>
  <arm_group>
    <arm_group_label>Oral morphine solution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral morphine solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Buprenorphine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sublingual buprenorphine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>buprenorphine</intervention_name>
    <description>sublingual buprenorphine administered every 8 hours, titrated to control of abstinence symptoms</description>
    <arm_group_label>Buprenorphine</arm_group_label>
    <other_name>Buprenex (buprenorphine)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral morphine solution</intervention_name>
    <description>0.4 mg/kg/day morphine every 4 hours</description>
    <arm_group_label>Oral morphine solution</arm_group_label>
    <other_name>morphine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  â‰¥ 37 weeks gestation

          -  exposure to opiates in utero

          -  demonstration of signs and symptoms of neonatal abstinence syndrome requiring
             treatment

        Exclusion Criteria:

          -  major congenital malformations and/or intrauterine growth retardation

          -  medical illness requiring intensification of medical therapy

          -  concomitant benzodiazepine or severe alcohol abuse, self-report of regular use of
             alcohol or of benzodiazepines use in the past 30 days, and/or receipt of
             benzodiazepines by prescription (as determined by self-report or intake urine) by the
             mother during pregnancy,

          -  concomitant use of CYP 3A inhibitors (erythromycin, clarithromycin, ketoconazole,
             itraconazole, HIV protease inhibitors) or inducers (rifampin, carbamazepine,
             phenobarbital) prior to initiation of NAS treatment

          -  seizure activity or other neurologic abnormality

          -  breast feeding

          -  inability of mother to give informed consent due to co-morbid psychiatric diagnosis

          -  hypoglycemia requiring treatment with intravenous glucose
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walter K Kraft, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Kraft WK, Gibson E, Dysart K, Damle VS, Larusso JL, Greenspan JS, Moody DE, Kaltenbach K, Ehrlich ME. Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial. Pediatrics. 2008 Sep;122(3):e601-7. doi: 10.1542/peds.2008-0571. Epub 2008 Aug 11.</citation>
    <PMID>18694901</PMID>
  </results_reference>
  <results_reference>
    <citation>Kraft WK, Dysart K, Greenspan JS, Gibson E, Kaltenbach K, Ehrlich ME. Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome. Addiction. 2011 Mar;106(3):574-80. doi: 10.1111/j.1360-0443.2010.03170.x. Epub 2010 Oct 6.</citation>
    <PMID>20925688</PMID>
  </results_reference>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2007</study_first_submitted>
  <study_first_submitted_qc>August 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2007</study_first_posted>
  <last_update_submitted>January 11, 2017</last_update_submitted>
  <last_update_submitted_qc>January 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2017</last_update_posted>
  <responsible_party>
    <name_title>Steve Oversby</name_title>
    <organization>NIDA</organization>
  </responsible_party>
  <keyword>Neonatal Abstinence Syndrome</keyword>
  <keyword>buprenorphine</keyword>
  <keyword>neonatal</keyword>
  <keyword>opioid withdrawal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Neonatal Abstinence Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Buprenorphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

